Peptides represent a therapeutic class with genuine biological activity, requiring the same scrutiny applied to pharmaceutical interventions rather than supplements. The distinction between evidence-supported peptide applications and marketed claims determines whether they function as targeted tools or sources of unquantified risk.
Key Points
- Peptides are pharmacologically active; careless use carries real medical consequences
- Marketing claims frequently outpace clinical evidence and regulatory oversight
- Rigorous evaluation protocols separate legitimate therapeutic applications from speculation
Longevity Analysis
Peptides operate across multiple physiological pathways—regulating hormonal signaling, supporting regeneration, modulating stress response, and influencing energy metabolism. The critical distinction lies not in whether peptides can support longevity optimization, but in whether their application is informed by mechanism of action, dose-response relationships, and individual biochemical context. Indiscriminate peptide use introduces uncontrolled variables into systems that require precise calibration, whereas evidence-informed peptide protocols can support specific physiological adaptations when integrated into comprehensive longevity strategies.
Original published by Peter Attia MD, by Peter Attia.